CA-4948 is also being tested in AML (NCT04278768) and so far, preliminary data show 4 of 4 patients with FLT3 and spliceosome mutations treated with monotherapy had an objective response with a decrease in marrow blast percentage. Here, FLT3 is linked to acute myeloid leukemia.